Company Project Advancement - The company is actively promoting the market launch and sales of calcium silicate bio-ceramic oral bone repair materials, planning to adopt a differentiated marketing strategy based on product innovation advantages [1] - The meningeal series products have won bids in 24 provinces for volume procurement projects, with the Beijing-Tianjin-Hebei "3+N" alliance procurement project set to start in December 2025, and the company is progressing with related preparations as planned [1] Product Development Progress - The uterine cavity repair membrane is set to enter the registration phase in early January 2026, having received the registration acceptance notice [2] - The breast patch is expected to complete clinical trial summaries by November 2025, and preparations for registration are currently underway [2] Company Business Status - In 2026, the company plans to accelerate the market promotion and terminal volume of active biological bone to enhance revenue contribution [3] - Several products have export potential, and the company is evaluating market access requirements and feasibility in different countries and regions, conducting preliminary preparation work [3]

Group 1 - The core viewpoint of the article is that Zhenghai Bio is actively monitoring policies and developments related to mergers and acquisitions, indicating a potential openness to consider such strategies for growth [1] - Zhenghai Bio acknowledges the importance of balancing stable operations with capital operations, suggesting a strategic approach to future investments [1] - The company commits to following legal procedures and timely information disclosure regarding any developments in mergers and acquisitions [1]

Core Viewpoint - Zhenghai Biological (300653) is effectively managing production and shipment based on customer orders, ensuring that overall capacity is operating efficiently and normally [1] Group 1: Production and Capacity - The company has established an independent production line for calcium silicate biological ceramic oral bone repair materials ahead of its certification and market launch [1] - The current production line is capable of stable and efficient product manufacturing, with capacity fully meeting the anticipated market demand for the products [1]

Core Viewpoint - The company is effectively managing its production capacity to meet market demand for its products, particularly in the field of calcium silicate bioceramics for dental bone repair [2]. Group 1: Production Capacity - The company reported that its overall production capacity is operating within a normal and efficient range, responding to customer order demands [2]. - A dedicated production line for calcium silicate bioceramics has been established prior to product certification and market launch, ensuring stable and efficient production [2]. Group 2: Market Demand - The production capacity of the new product line is sufficient to meet the anticipated market demand for calcium silicate bioceramics [2].

Group 1 - The core viewpoint is that the dental implant market in China has significant growth potential due to reduced medical costs from price limits on implant services and collective procurement initiatives, which have stimulated demand for dental implants [1] - The penetration rate of dental implants in China remains low compared to developed countries like the US and South Korea, indicating substantial room for growth in this sector [1] - The company is optimistic about the long-term development potential of the dental implant industry and plans to continue focusing on this advantageous area while promoting new products to expand market space [1] Group 2 - In the area of meninges products, the company benefits from the comprehensive implementation of collective procurement policies and a high domestic production rate, leading to a mature and stable industry development [1] - The company has actively participated in collective procurement projects and has consistently won bids, which has helped to solidify and enhance its market share in the meninges product segment [1] - The meninges product line is expected to become a key revenue driver for the company, providing a stable income base due to the stability of the industry and the market position of its products [1]

Core Viewpoint - Zhenghai Biological has initiated the registration phase for its intrauterine repair membrane product, having received the registration acceptance notice, with further evaluation and approval steps to follow [1] Group 1 - The intrauterine repair membrane product was officially pushed into the registration phase in early January 2023 [1] - The company has completed the clinical trial summary for its breast patch project by November 2025 and is currently preparing for product registration [1] - The company will fulfill its information disclosure obligations in accordance with regulatory requirements regarding the progress of product development [1]

Core Viewpoint - Zhenghai Biological has prepared for the market launch of its calcium silicate bioceramic oral bone repair materials, ensuring sufficient production capacity and a strategic marketing approach to maximize profitability [1] Group 1: Product Overview - The calcium silicate bioceramic oral bone repair materials are designed for use in conjunction with barrier membranes and are suitable for repairing alveolar bone defects [1] Group 2: Market Preparation - The company has proactively engaged in product transition and brand promotion before obtaining product certification, ensuring readiness for a swift market entry [1] - Sufficient production capacity has been established to facilitate rapid sales following the product launch [1] Group 3: Marketing Strategy - The product promotion strategy will leverage the innovative advantages in raw material composition and process structure, tailored to the comprehensive conditions of the target market [1] - A differentiated marketing strategy will be employed to enhance product market penetration and profitability [1]

Core Viewpoint - Zhenghai Biological reported a decrease in revenue from oral repair membranes, primarily due to price fluctuations and intensified competition in the private dental market, leading to a slowdown in the growth trend of dental implant demand [1] Group 1: Market Conditions - The oral private market has been affected by increased competition and cost-cutting measures at the terminal level, which have contributed to the decline in revenue [1] - The growth trend of dental implant demand is slowing down, impacting overall market performance [1] Group 2: Company Strategy - In response to market competition, the company is implementing a precise marketing strategy to leverage its advantages in scale and cost [1] - The company is optimizing product pricing and enhancing close cooperation with leading terminals to stabilize market share coverage [1] - The oral segment remains a key focus for the company, which plans to continue deepening its efforts in this area and accelerate the launch and sales of new oral products [1] Group 3: Competitive Position - The company aims to strengthen its core competitiveness by synergizing the capabilities of membrane and powder product combinations [1]

Core Viewpoint - The company, Zhenghai Biological, indicated that it will consider the necessity of financing and specific financing plans based on future development strategies and overall capital structure [2] Group 1 - The company is open to financing options as part of its strategic development [2] - Future financing plans will be aligned with the company's capital structure considerations [2]

Group 1 - Zhenghai Biological announced that on January 20, 2026, it will be receiving a research visit from Huaxi Securities, with the company's board secretary, vice general manager, and chief financial officer, Ms. Zhao Li, participating in the reception and answering investor questions [1]